Introducing a New Dimension to Molecular Disease Classifications

Trends in Molecular Medicine

Volumn 22, Issue 6, 2016, Pages 451-453

  Jourde Chiche, Noémie ^a   Chiche, Laurent ^b   Chaussabel, Damien ^c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b Européen Hospital   (France)

^c SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERFERON; NEUTRALIZING ANTIBODY;

CHILDHOOD DISEASE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; PERSONALIZED MEDICINE; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; AUTOIMMUNE DISEASE; IMMUNOLOGY;

AUTOIMMUNE DISEASES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84965077435     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.04.005     Document Type: Short Survey

References (8)

1. Banchereau R., et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 2016, Published online March 30, 2016. 10.1016/j.cell.2016.03.008.
2. Bennett L., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003, 197:711-723.
3. Baechler E.C., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2610-2615.
4. Chiche L., et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 2014, 66:1583-1595.
5. Khamashta M., et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 2016, Published online March 23, 2016. 10.1136/annrheumdis-2015-208562.
6. Kalunian K.C., et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann. Rheum. Dis. 2016, 75:196-202.
7. Chaussabel D., et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008, 29:150-164.
8. Chaussabel D., Baldwin N. Democratizing systems immunology with modular transcriptional repertoire analyses. Nat. Rev. Immunol. 2014, 14:271-280.